Literature DB >> 30357594

Fruquintinib: First Global Approval.

Matt Shirley1.   

Abstract

Fruquintinib (Elunate®) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours. In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies. Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer. This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30357594     DOI： 10.1007/s40265-018-0998-z

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  8 in total

Review 1.  Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.

Authors:  Haizhen Zhong; J Phillip Bowen
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 2.  Monoclonal antibodies in cancer therapy.

Authors:  Andrew M Scott; James P Allison; Jedd D Wolchok
Journal:  Cancer Immun       Date:  2012-05-01

3.  A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.

Authors:  Sufeng Zhou; Feng Shao; Zhaoqiang Xu; Lu Wang; Ke Jin; Lijun Xie; Juan Chen; Yun Liu; Hongwen Zhang; Ning Ou
Journal:  Cancer Chemother Pharmacol       Date:  2017-07-20       Impact factor: 3.333

4.  Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.

Authors:  Shun Lu; Jianhua Chang; Xiaoqing Liu; Jianhua Shi; You Lu; Wei Li; Jin-Ji Yang; Jianying Zhou; Jie Wang; Tongtong An; Lei Yang; Zhe Liu; Xiangdong Zhou; Mo Chen; Ye Hua; Weiguo Su
Journal:  J Clin Oncol       Date:  2018-03-12       Impact factor: 44.544

5.  Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.

Authors:  Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng; Zhen-Dong Chen; Haijun Zhong; Hongming Pan; Weijian Guo; Yongqian Shu; Ying Yuan; Jianfeng Zhou; Nong Xu; Tianshu Liu; Dong Ma; Changping Wu; Ying Cheng; Donghui Chen; Wei Li; Sanyuan Sun; Zhuang Yu; Peiguo Cao; Haihui Chen; Jiejun Wang; Shubin Wang; Hongbing Wang; Songhua Fan; Ye Hua; Weiguo Su
Journal:  JAMA       Date:  2018-06-26       Impact factor: 56.272

6.  Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.

Authors:  Rui-Hua Xu; Jin Li; Yuxian Bai; Jianming Xu; Tianshu Liu; Lin Shen; Liwei Wang; Hongming Pan; Junning Cao; Dongsheng Zhang; Songhua Fan; Ye Hua; Weiguo Su
Journal:  J Hematol Oncol       Date:  2017-01-19       Impact factor: 17.388

7.  A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.

Authors:  Junning Cao; Jian Zhang; Wei Peng; Zhiyu Chen; Songhua Fan; Weiguo Su; Ke Li; Jin Li
Journal:  Cancer Chemother Pharmacol       Date:  2016-06-14       Impact factor: 3.333

8.  Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.

Authors:  Qiaoling Sun; Jinghong Zhou; Zheng Zhang; Mingchuan Guo; Junqing Liang; Feng Zhou; Jingwen Long; Wei Zhang; Fang Yin; Huaqing Cai; Haibin Yang; Weihan Zhang; Yi Gu; Liang Ni; Yang Sai; Yumin Cui; Meifang Zhang; Minhua Hong; Junen Sun; Zheng Yang; Weiguo Qing; Weiguo Su; Yongxin Ren
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742
  8 in total
  14 in total

1.  Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.

Authors:  Mohammad M Al-Sanea; Ghada H Al-Ansary; Zainab M Elsayed; Raed M Maklad; Eslam B Elkaeed; Mohamed A Abdelgawad; Syed Nasir Abbas Bukhari; Marwa M Abdel-Aziz; Howayda Suliman; Wagdy M Eldehna
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

2.  Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling.

Authors:  Xiaomin Cai; Bin Wei; Lele Li; Xiaofeng Chen; Jing Yang; Xiaofei Li; Xiaozheng Jiang; Mu Lv; Mingyang Li; Yumeng Lin; Qiang Xu; Wenjie Guo; Yanhong Gu
Journal:  Onco Targets Ther       Date:  2020-10-29       Impact factor: 4.147

3.  Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?

Authors:  Qi Zhang; Qianqian Wang; Xicheng Wang; Jian Li; Lin Shen; Zhi Peng
Journal:  Int J Colorectal Dis       Date:  2019-12-17       Impact factor: 2.571

Review 4.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

Review 5.  Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.

Authors:  Shuang Qin; Anping Li; Ming Yi; Shengnan Yu; Mingsheng Zhang; Kongming Wu
Journal:  J Hematol Oncol       Date:  2019-03-12       Impact factor: 17.388

6.  Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.

Authors:  Yinying Wu; Yangwei Fan; Danfeng Dong; Xuyuan Dong; Yuan Hu; Yu Shi; Jiayu Jing; Enxiao Li
Journal:  Ther Adv Med Oncol       Date:  2020-07-15       Impact factor: 8.168

7.  Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer.

Authors:  Yefei Shu; Song Zheng
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

Review 8.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

9.  Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.

Authors:  Ying Zhang; Jia-Yun Zou; Zhe Wang; Ying Wang
Journal:  Cancer Manag Res       Date:  2019-08-16       Impact factor: 3.989

10.  Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization.

Authors:  Xiaojuan Liu; Aisong Guo; Yuanyuan Tu; Wendie Li; Lele Li; Wangrui Liu; Yuanyuan Ju; Yamei Zhou; Aimin Sang; Manhui Zhu
Journal:  Cell Death Dis       Date:  2020-11-27       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.